Mianyang Central Hospital   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Mianyang China (1939)

Organization Overview

First Clinical Trial
2014
NCT02076477
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Mianyang Central Hospital | Mian Yang Central Hospital | Qian Gong | Yao Liao

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Squamous Cell (Phase 4)

Cerebral Infarction (Phase 4)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Dermatitis (Phase 4)

Heart Diseases (Phase 2)

Ischemia (Phase 4)

Lung Neoplasms (Phase 3)

Myocardial Ischemia (Phase 2)

Radiodermatitis (Phase 4)

Squamous Cell Carcinoma of Head and Neck (Phase 4)

Stroke (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 15